

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Healthcare provider-targeted mobile applications to diagnose, screen, or monitor communicable diseases of public health importance in low- and middle-income countries: a systematic review

Pascal Geldsetzer^{1,2,3†}, Sergio Flores^{4†}, Blanca Flores⁵, Abu Bakarr Rogers⁶, Andrew Y Chang^{3,7,8*}

Author Affiliations:

¹ Division of Primary Care and Population Health, Department of Medicine, Stanford University; Stanford, CA; USA

² Chan Zuckerberg Biohub; San Francisco, CA; USA

³ Center for Innovation in Global Health, Stanford University; Stanford, CA; USA

⁴ Department of Public Health and Caring Sciences, Uppsala University; Sweden

⁵ Heidelberg University Hospital, Heidelberg; Germany

⁶ Stanford University School of Medicine; Stanford, CA; USA

⁷ Department of Epidemiology and Population Health, Stanford University; Stanford, CA; USA

⁸ Stanford Cardiovascular Institute, Stanford University; Stanford, CA; USA

***Corresponding Author:**

Andrew Young Chang, MD MS

E-mail: aychang@stanford.edu

† These authors contributed equally to this work

Short Title: mHealth Technologies Targeting Communicable Diseases in LMICs

27 **Abstract**

28 Communicable diseases remain a leading cause of death and disability in low-
29 and middle-income countries (LMICs). mHealth technologies carry considerable
30 promise for managing these disorders within resource-poor settings, but many existing
31 applications simply represent digital versions of existing guidelines or clinical
32 calculators, communication facilitators, or patient self-management tools.

33 We thus systematically searched PubMed, Web of Science, and Cochrane
34 Central for studies published between January 2007 and October 2019 involving
35 technologies that were mobile phone- or tablet-based; able to screen for, diagnose, or
36 monitor a communicable disease of importance in LMICs; and targeted health
37 professionals as primary users. We excluded technologies that merely digitized existing
38 paper-based tools or simply facilitated communication. Extracted data included disease
39 category, pathogen type, diagnostic method, intervention purpose, study/target
40 population, sample size, study methodology, development stage, accessory
41 requirement, country of development, operating system, and cost. Given the search
42 timeline and the extremely rapid turnover in the science concerning Coronavirus
43 Disease 2019 and its novel variants, studies involving it were not included in the
44 analysis.

45 Of 13,262 studies identified by the screen, 33 met inclusion criteria. 12% were
46 randomized clinical trials (RCTs), with 58% of publications representing technical
47 descriptions. 62% of studies had 100 or fewer subjects. All studied technologies
48 involved diagnosis or screening steps; none addressed the monitoring of infections.
49 52% focused on priority diseases (HIV, malaria, tuberculosis), but only 12% addressed

50 a neglected tropical disease. Although most reported studies were priced under 20USD
51 at time of publication, two thirds of the records did not yet specify a cost for the study
52 technology.

53 We conclude that there are only a small number of mHealth technologies
54 focusing on innovative methods of screening and diagnosing communicable diseases
55 potentially of use in LMICs. Rigorous RCTs, analyses with large sample size, and
56 technologies assisting in the monitoring of diseases are needed.

57

58

59

60 **Keywords:** *mHealth; mobile technology; apps; digital health; communicable diseases;*

61 *infectious diseases; global health; LMIC*

62

63 **Author Summary**

64 Although significant progress has been made in decreasing their worldwide
65 impact, infectious diseases still represent a considerable burden of disease and death.
66 This is especially the case in certain regions of low- and middle-income countries,
67 where limited healthcare resources, personnel, and facilities can make it difficult to
68 provide high quality care. Mobile health (mHealth) technologies are disruptive tools that
69 hold considerable promise in these resource-constrained settings by circumventing
70 some of the aforementioned obstacles.

71 To better understand the availability and characteristics of mHealth technologies
72 for use in low- and middle-income countries, we systematically searched for studies
73 published in English between January 2007 through October 2019 to identify all existing
74 mobile phone- or tablet-based innovations targeted at healthcare providers for use
75 against infectious diseases in these settings and summarized their qualities and
76 performance.

77 We found that four times as many publications focused on tools that simply made
78 data transfer more simple than there were on new tools for detecting or monitoring
79 diseases. Few studies were tested under the most rigorous scientific methods. Many
80 diagnostic technologies we identified require specialized attachments or additional
81 laboratory equipment that connect to the smartphone or tablet, which could make their
82 use in some settings more challenging.

83

84 **Introduction**

85 As of 2019, communicable diseases were still the main driver of disability-adjusted life
86 years (DALYs) in children under ten years of age globally and were responsible for six
87 out of the top ten global causes of DALYs (1). In 2017, 35% of the years of life lost
88 worldwide were from communicable, maternal, neonatal, and nutrition-related disorders
89 (2). Communicable diseases not only increase mortality and reduce life expectancy in
90 LMICs, but they also cause significant disability, leading to loss of economic productivity
91 in impacted communities (1). Furthermore, nearly a tenth of the global burden of non-
92 communicable diseases (NCDs) that year were attributed to an infectious cause, with
93 the burden quantified to be 130 million DALYs (3). Additionally, many LMICs continue to
94 be afflicted by neglected tropical diseases such as dengue virus, Chagas disease, and
95 schistosomiasis. These are not only unique to these regions but also endemic,
96 remaining a major contributor to morbidity and mortality in those settings (4–6).

97
98 The persistence of communicable diseases in LMICs is thought to be due to a number
99 of factors, including incomplete development of robust public health infrastructure,
100 shortage of healthcare providers, and continuance of major health disparities (4). New
101 technologies could help overcome these obstacles to further accelerating the reduction
102 in the communicable disease burden in LMICs. For one, such technologies could
103 enable task shifting from physicians to nurses and community health workers (CHWs)
104 with the goal of alleviating the shortage of more highly trained healthcare worker cadres
105 in low-resource settings. One venue for doing so involves equipping such personnel
106 with mobile health (mHealth) technologies, whose simplified user interfaces, integrated

107 workflow protocols, and lower costs would be ideal for extending the practice
108 capabilities of their users (7). For example, incorporating mHealth apps in routine CHW
109 activities has been shown to be beneficial in process improvement and technology
110 development, standards and guidelines, education and training, and leadership and
111 management (8). mHealth devices have already been demonstrated to improve the
112 management of infectious diseases in many instances in low-resource settings, (9,10)
113 as they can serve as rapid and cheap diagnostic tools (11,12). The wireless, portable
114 aspects of many such technologies also increase the accessibility of healthcare
115 services to patients by reducing travel time and expenses (8).

116

117 The current published literature contains many reports of apps that simply digitize
118 existing algorithms or facilitate inter-provider or patient-provider communication. To the
119 best of our knowledge, however, it does not offer a comprehensive, up-to-date
120 systematic review of truly innovative, novel provider-facing mHealth technologies
121 available for infectious disease care in LMIC settings. These include technologies such
122 as simplified laboratory testing equipment with smart device interfaces and artificial
123 intelligence-guided diagnostic tools. As such, we conducted a systematic review that
124 aims to identify all existing novel mobile phone- or tablet-based innovations targeted at
125 healthcare providers and summarize the performance of these technologies.

126

127 **Methods**

128 **Search Strategy**

129 We searched for all studies published in English from January 2007 through October
130 2019 in the following databases: Cochrane Central (searched on September 30th,
131 2019), PubMed (searched on October 7th, 2019), and Web of Science (searched on
132 October 7th, 2019). The databases were queried using keywords and medical subject
133 headings (MeSH) including those attributable to smartphones, tablets, diagnosis,
134 screening, and monitoring. A full list of the search terms used for each database are
135 shown in **S1 Table**. The database searches, examination of abstracts, and inspection of
136 articles' full-text versions were not conducted in duplicate. No restrictions were placed
137 on study design, sample size, or publication type. Finally, the reference lists of all
138 included studies, relevant review articles, and commentaries were screened for
139 additional references. The search process is summarized in **Figure 1**. The review was
140 registered in The International Prospective Register of Systematic Reviews
141 (PROSPERO; Registration number: CRD42020193945) (13). Ethical approval was not
142 sought from the Stanford institutional review board as the study did not constitute
143 human subjects research and consisted only of meta-research (which is exempt by
144 definition).

145

146

147


148

149

150

Figure 1. PRISMA Diagram

151



**Other reasons: abstracts, protocols, personal reviews, nonhuman testing.*

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

152

For more information, visit www.prisma-statement.org.

153

154 **Inclusion and Exclusion Criteria**

155 Titles and abstracts were screened for pertinence, and if inconclusive, the full-text
156 versions of articles were evaluated for adequacy utilizing the following inclusion criteria:

- 157 i) The technology reported must be mobile phone or tablet-based for their
158 clinical function—this excludes mobile devices and applications that solely
159 use their internet connectivity to transmit data;
- 160 ii) The technology must target healthcare professionals specifically as users—
161 tools used to educate patients, change patient behaviors as consumer
162 products, or improve patient-provider communication were excluded;
- 163 iii) The technology reported must be able to screen, diagnose, or monitor a
164 disease;
- 165 iv) The technology must represent an innovation—applications simply used to
166 keep records, reproduce existing guidelines and clinical calculators in digital
167 form, or facilitate communication between providers were excluded; and
- 168 v) The disease the technology is designed to address must be a communicable
169 disease of public health importance for LMICs. Such diseases were defined
170 as infectious conditions that are estimated to cause more than 1% of deaths
171 in any five-year age group in the general population or among neonates, or
172 infectious diseases that have a prevalence of more than 0.1% in any five-year
173 age group in the general population or among neonates. The Global Burden
174 of Disease Project's 2019 estimates were utilized for this appraisal (14).

175

176 Of note, given the timeline of the search and the extremely rapid turnover in the
177 science surrounding the disease and its many novel variants, studies involving
178 Coronavirus Disease 2019 (COVID-19) were not included in the present analysis.

179

180 **Data Extraction**

181 The following data were extracted from each included article: author(s), title, disease or
182 risk factor, clinical domain by MeSH (15), intervention name, intervention type, purpose
183 and aim of the intervention, target population, type of diagnostic method, type of
184 pathogen studied (by microbial class, LMIC priority disease (namely Human
185 Immunodeficiency Virus (HIV), tuberculosis and malaria), as well as neglected tropical
186 disease (NTD) status as defined by the World Health Organization (16), type of mobile
187 device utilized, type of software, operating system used by intervention, study
188 population and sample size, study methods, stage of development, cost in US dollars
189 (USD) at the time of publication (all dollar figures are given as published in the
190 manuscript and not adjusted for inflation, and in the case of articles reporting currencies
191 other than dollars, were converted to 2021 US dollars (17)), country of development
192 based on first authors' institutional affiliations, location of testing based on the study
193 population country of residence, institutional nation of all listed authors, year of
194 publication, and a summary of the tool (**S2 Table**). These data were extracted
195 qualitatively using Microsoft Excel (Redmond, WA).

196

197 **Data Analysis**

198 Quantitative data were summarized with counts and proportions. The retrieved data
199 were organized into three themes: epidemiology, technology, and methodology. The
200 epidemiology theme described the disease of interest (and whether it is categorized as
201 an LMIC priority disease by the Global Health National Academies of Science (18) or
202 diseases that were among the top ten in terms of disability-adjusted life years caused
203 globally in 2019 (19)), its characteristics, and the geographic location of the
204 intervention's development. The technology theme described the primary hardware
205 platform of the innovation, necessary peripherals, as well as the operating system it
206 utilized and its cost considerations. The methodology theme evaluated the phase of
207 study and research design of each publication. **S2 Table** lists these themes, as well as
208 the categories, subcategories, and definitions that accompany them. To elucidate trends
209 among the studies, we created tables that crossed clinical categories and included all
210 the subthemes. We decided against conducting a meta-analysis due to the substantial
211 degree of heterogeneity in study designs, outcome measurements, and reporting of
212 results. As such, we employed a qualitative measure of study quality on a three-tiered (-
213 , +, and ++) system to characterize publication quality as unsound, suboptimal, or
214 sound, based upon the *British Medical Journal's* Evidence Based Medicine Best
215 Practice Toolkit (20).

216

217 **Results**

218 Our initial search of all the above databases retrieved 13,262 results. After duplicates
219 were removed, abstracts screened, full texts reviewed, and articles identified from

220 reference lists of included articles were added, 33 studies met our inclusion criteria
 221 **(Figure 1, S3 Table)**. Articles were excluded if they described or evaluated: i)
 222 interventions not meant for diagnosis, screening and/or monitoring (n=49); ii) non-
 223 mobile technology-based interventions (n=85); iii) interventions targeting patients
 224 instead of health professionals as users (n=43); iv) the general status of current
 225 technologies (n=48); v) non communicable diseases (n=317), or that vi) did not have a
 226 full text available (n=41); vii) were not available in English (n=14); viii) were systematic
 227 reviews (n=36); ix) were study protocols or involved non-human testing (n=8); or x)
 228 presented technology that merely digitalized protocols, scores or other procedures that
 229 could be done on paper (n=103). An overview of the included studies' characteristics is
 230 presented in **Table 1** and the full list of identified studies is available in **S3 Table**.

231
 232
 233
 234

Table 1. Characteristics of Studies

| | | Count | Percentage of Total |
|---|--|--------------|----------------------------|
| <i>Year of Publication</i> (Total N=33) | 2006-2008 | 0 | 0% |
| | 2009-2011 | 1 | 3% |
| | 2012-2014 | 6 | 18% |
| | 2015-2017 | 15 | 45% |
| | 2018-2020 | 11 | 33% |
| <i>Location of Study</i> (Total N=33) | United States | 13 | 39% |
| | Americas (excluding the United States) | 3 | 9% |
| | Europe | 3 | 9% |
| | Africa | 9 | 27% |
| | Asia | 5 | 15% |
| <i>Affiliation of Researchers</i> (Total N=61) | United States | 24 | 39% |
| | Americas (excluding the United States) | 7 | 11% |
| | Europe | 14 | 23% |
| | Africa | 9 | 15% |
| | Asia | 7 | 11% |
| <i>Aim</i> (Total N=35) | Diagnose | 26 | 74% |
| | Screen | 9 | 26% |
| | Monitor | 0 | 0% |
| <i>Diagnostic Method</i> (Total N=35) | Direct Visualization | 10 | 29% |
| | Serology | 11 | 31% |
| | Antigen Detection | 1 | 3% |
| | Nucleic Acid Detection | 10 | 29% |
| | Others | 3 | 9% |

| | | | |
|--|---|----|-----|
| <i>Type of Pathogen Studied (Total N=42)</i> | Viral | 18 | 43% |
| | Bacterial | 14 | 33% |
| | Parasitic | 10 | 24% |
| <i>Type of Device (Total N=36)</i> | Armband/ Smartwatch | 0 | 0% |
| | Smartphone | 29 | 81% |
| | Non-Smartphone Mobile Phone | 1 | 3% |
| | Tablet | 4 | 11% |
| | iPod Device | 1 | 3% |
| <i>Requires Use of Accessories (Total N=33)</i> | Another wireless device | 1 | 3% |
| | Yes | 26 | 79% |
| | No | 7 | 21% |
| <i>Development Stage (Total N=33)</i> | Proof of Concept/Principle | 1 | 3% |
| | In development | 1 | 3% |
| | Prototype | 11 | 33% |
| | Pilot | 0 | 0% |
| | Validation Trial/Test in Clinical Trial | 2 | 6% |
| | Available/Developed | 17 | 52% |
| <i>Operating System (Total N=34)</i> | Not specified | 1 | 3% |
| | iOS | 11 | 32% |
| | Android | 18 | 53% |
| | Windows | 1 | 3% |
| | Not specified | 4 | 12% |
| <i>Cost at Time of Publication (Total N=33)</i> | 0-20 USD | 8 | 24% |
| | 21-100 USD | 2 | 6% |
| | Over 100 USD | 1 | 3% |
| | Not specified/no costing yet | 22 | 67% |
| <i>Study Population Sample Size (Total N=33)</i> | 1-30 | 7 | 21% |
| | 31-100 | 6 | 18% |
| | 101-500 | 4 | 12% |
| | 501-1000 | 1 | 3% |
| | >1000 | 3 | 9% |
| | None/Not specified | 12 | 36% |
| <i>Study Design (Total N=33)</i> | Randomized Clinical Trials | 4 | 12% |
| | Observational Cohort Studies / Case-Control Studies | 9 | 27% |
| | Qualitative Studies | 1 | 3% |
| | Product / Technical Description | 19 | 58% |
| <i>Study Quality (Total N=33)</i> | - (unsound) | 0 | 0% |
| | + (suboptimal) | 8 | 24% |
| | ++ (sound) | 25 | 76% |
| <i>Evaluation Values Used (Total N=39)</i> | Measures of Diagnostic Accuracy | 22 | 56% |
| | Variability Measures | 5 | 13% |
| | Correlation Values | 3 | 8% |
| | Intraobserver and interobserver values | 1 | 3% |
| | Measurement Error Analysis | 0 | 0% |
| | Diverse Measurement Results | 5 | 13% |
| | Bland Altman Analysis | 1 | 3% |
| | None/Not specified | 2 | 5% |

235

236 Epidemiology

237 Most studies described technologies tested predominantly in the United States (13/33),

238 the rest of the Americas (3/33), followed by Africa (9/33), then Asian countries (5/33)

239 and Europe (3/33). The affiliation of the first author's institutions is located
240 predominantly in the United States (24/61), with fewer based in the Americas (7/61),
241 Europe (14/61), Africa (9/61) and Asia (7/61). A noteworthy observation is that all the
242 studies save one (32/33) involved at least one researcher affiliated with a high-income
243 country institution, even if the research was ultimately conducted in an LMIC.

244
245 Most of the identified technologies focus on the diagnosis of communicable diseases
246 (26/35), while the rest aim to screen for (9/35) these diseases. No study expressed
247 monitoring as the main aim of their technology. The diagnostic method of choice chosen
248 by the researchers was most often serological methods (11/35), followed by direct
249 visualization of the microorganisms (10/35) and nucleic acid detection (10/35). The
250 technologies targeted viral (18/42), bacterial (14/42), and parasitic (10/42) infections.

251
252 Almost half (17/33) of the included studies addressed an LMIC priority disease. Only a
253 small number of technologies (4/33) targeted a neglected tropical disease. **Table 2**
254 describes the 16 studies of technologies aimed at diseases that were among the top ten
255 in terms of disability-adjusted life years (DALYs) caused globally in 2019. Specifically,
256 these studies targeted drug-susceptible tuberculosis, malaria, diarrheal diseases, and
257 lower respiratory infections.

258

259 **Table 2: Studies of technologies addressing diseases among the top ten in disability-adjusted life years globally in 2019**

| Title | Authors | Disease/ Risk factor | Pathogen Name | Pathogen Family/Category | Mobile Device Type | Operating System | Diagnostic Method | Clinical Domain | Researchers' Country (or countries) | Country where Research was Conducted |
|---|--|--------------------------|---|--|-----------------------|---------------------|--|--|---|--|
| App-based symptoms screening with Xpert MTB/RIF Ultra assay used for active tuberculosis detection in migrants at point of arrivals in Italy: The E-DETECT TB intervention analysis | Barcellini, L. et al. | Pulmonary tuberculosis | <i>Mycobacterium tuberculosis</i> | Mycobacteriaceae/ Opportunistic infection | Smartphone | Android | Nucleic Acid Detection/ Organism visualization | Infectious diseases specialists/ Pulmonology | Italy/United Kingdom | Italy |
| Evaluation of a Mobile Phone-Based Microscope for Screening of <i>Schistosoma haematobium</i> Infection in Rural Ghana. | Bogoch, I. et al. | Schistosomiasis | <i>Schistosoma haematobium</i> | Soil-transmitted helminthiasis | Smartphone | Windows | Organism visualization | Infectious diseases specialists/ Pediatrics/Family medicine | United States/Canada/ Ghana | Ghana |
| Mobile phone based clinical microscopy for global health applications. | Breslauer, D. et al. | Malaria/ Pulmonary TB | <i>P. falciparum</i> / <i>M. tuberculosis</i> | Vector Borne Diseases/ Mycobacteriaceae- Opportunistic infection | Mobile Phone | Symbian | Organism visualization | Infectious diseases specialists | United States | United States |
| Evaluation of Malaria Diagnoses Using a Handheld Light Microscope in a Community-Based Setting in Rural Cote d'Ivoire. | Coulibaly, J. et al. | Malaria | <i>Plasmodium falciparum</i> | Vector Borne Diseases | Smartphone | iOS | Organism visualization | Infectious diseases specialists | Côte d'Ivoire/ Switzerland/ United States/ Canada | Côte d'Ivoire |
| Diagnosis of <i>Schistosoma haematobium</i> infection with a mobile phone-mounted Foldscope and a reversed-lens CellScope in Ghana. | Ephraim, R. et al. | Schistosomiasis | <i>Schistosoma haematobium</i> | soil-transmitted helminthiasis | Smartphone | iOS | Organism visualization | Infectious diseases specialists/ Pediatrics/Family medicine | United States/Canada/ Ghana/ Switzerland | Ghana |
| mPneumonia: Development of an Innovative mHealth Application for Diagnosing and Treating Childhood Pneumonia and Other Childhood Illnesses in Low-Resource Settings. | Ginsburg, A. et al. | Pneumonia | Not specified | Not specified | Tablet | Android | Mobile health (mHealth)- based applications (Integrated Management of Childhood Illness algorithm) | Infectious diseases specialists/ Pediatrics/Family medicine | United States/ Ghana | Ghana |
| A point-of-need enzyme linked aptamer assay for <i>Mycobacterium tuberculosis</i> detection using a smartphone | L. Li, Z. Liu, H. Zhang et al. | Pulmonary tuberculosis | <i>Mycobacterium tuberculosis</i> | Mycobacteriaceae/ Opportunistic infection | Smartphone | Android | Nucleic acid detection | Infectious diseases specialists/ Pulmonology | China | China |
| Rapid electrochemical detection on a mobile phone | Lillehoj, Peter B.; Ming-Chun Huang et al. | Malaria | <i>Plasmodium falciparum</i> | Vector Borne Diseases | Smartphone | Android | Nucleic acid detection | Infectious diseases specialists | United States | United States |

| | | | | | | | | | | |
|---|---|------------------|---|---|------------|-----------------|----------------------------------|--|---|----------------------------|
| Integrated rapid-diagnostic-test reader platform on a cellphone | Mudanyali, Onur; Stoyan Dimitrov, Uzaïr Sikora, et al | Malaria/ TB/ HIV | P. falciparum, P. vivax, P. ovale and P. malariae/ M. tuberculosis/ HIV | Vector Borne Diseases/ Mycobacteriaceae- Opportunistic infection/ STD | Smartphone | Android and iOS | Serology | Infectious diseases specialists/ Internal Medicine | United States | United States |
| Mobile phone-based evaluation of latent tuberculosis infection: proof of concept for an integrated image capture and analysis system | Naraghi, Safa; Tinashe Mutsvangwa, René Goliath et al | Latent TB | Mycobacterium sp | Mycobacteriaceae/ Opportunistic infection | Smartphone | Android | Tuberculin skin test induration. | Infectious diseases specialists/ Internal Medicine | South Africa/ United Kingdom | South Africa |
| The Malaria System MicroApp: A New, Mobile Device-Based Tool for Malaria Diagnosis | Oliveira; Allisson Dantas, Clara Prats, Mateu Espasa, et al | Malaria | Plasmodium falciparum | Vector Borne Diseases | Tablet | Android | Organism visualization | Infectious diseases specialists | Brazil/ Spain | Brazil |
| Malaria Diagnosis Using a Mobile Phone Polarized Microscope | Pirnstill, C.W. & Coté, G.L. | Malaria | Plasmodium chabaudi | Vector Borne Diseases | Smartphone | iOS | Organism visualization | Infectious diseases specialists | United States | United States |
| Artificial neural network models to support the diagnosis of pleural tuberculosis in adult patients | Seixas, J.M. et al. | Pleural Tb | Mycobacterium tuberculosis | Mycobacteriaceae/ Opportunistic infection | Tablets | Not specified | Artificial neural networks (ANN) | Infectious diseases specialists | Brazil/ Canada | Brazil |
| A paper-based microfluidic Dot-ELISA system with smartphone for the detection of influenza A | Wu, Di et al | Influenza | Influenza A virus | Orthomyxoviridae | Smartphone | Android | Serology | Infectious diseases specialists/ Family medicine | United States/ China | China |
| Deep Learning for Smartphone-based Malaria Parasite Detection in Thick Blood Smears | Yang, Feng et al | Malaria | Plasmodium falciparum | Vector Borne Diseases | Smartphone | Android | Organism visualization | Infectious diseases specialists | United States/ China/ Thailand | Bangladesh/ Thailand |
| Smartphone-Based Fluorescent Diagnostic System for Highly Pathogenic H5N1 Viruses | Yeo, Seon-Ju et al | Avian influenza | H5N1 virus | Orthomyxoviridae | Smartphone | Android | Serology | Infectious diseases specialists/ Family medicine | Republic of Korea/ Vietnam/ United States | Vietnam/ Republic of Korea |

261 **Technology**

262 The most popular device used in the studies was the smartphone (29/36), followed by
263 tablets (4/36) and mobile phones without smartphone capabilities (1/36). Technologies
264 were predominantly developed for the Android operating system (18/34) and Apple iOS
265 (iPhone Operating System) operating system (11/34), with Windows use present in just
266 one product (1/34). Four publications did not specify an operating system used by their
267 application. Most (26/33) of the mobile technologies required the use of peripheral
268 accessories attached to them such as additional optical components, 3D printed
269 attachments, foldscopes, cradles, and dongles. Cost data were not available for most
270 (22/33) technologies. For the technologies with costing information (11/33), most were
271 priced at less than 20 USD (8/11), followed by between 20 and 100 USD (2/11) and one
272 over 100 USD (1/11) at the time of study publication.

273

274 **Methodology**

275 Most studies focused on technologies in an advanced development stage, i.e., already
276 developed and/or commercially available (17/33) followed by studies describing
277 prototypes (11/33). Regarding research design, most studies focused on descriptions of
278 the technology without a formal evaluation of its efficacy or effectiveness (19/33) or
279 assessed the technology using an observational cohort design (9/33). Only a few
280 technologies were evaluated using a randomized design (4/33). Most publications
281 reported study population sizes of less than 30 participants (7/33), followed by study
282 sizes between 31 and 100 participants (6/33), then by study sizes between 101 and 500

283 (4/33) and over 1,000 subjects (1/33). Twelve studies did not specify a study population
284 size.

285

286 Discussion

287 Principal Results

288 The aim of our study was to identify and describe mobile-based technologies targeted
289 specifically at healthcare workers to screen, diagnose, and monitor communicable
290 diseases of public health importance in LMICs. We focused on technologies that
291 constituted a new tool rather than merely a digitization of an existing paper-based tool
292 or providing a means of communicating between healthcare providers. Our screening
293 found that there were four to five times as many publications on tools that merely
294 facilitated communication, transferred data, or digitized an existing paper-based
295 algorithm than there were on truly new tools for screening, diagnosing, and monitoring
296 diseases. Additionally, we found that most technologies described in our study were
297 tested in high-income countries using predominantly smartphones as mobile device and
298 Android as the operating system of choice. All but one of the included studies involved
299 at least one author affiliated with a high-income country research institution, with 42% of
300 first authors reporting institutional affiliations in the United States or Europe.

301

302 Although half of the technologies were already at an advanced stage of development,
303 few were tested under the rigor of large-scale randomized controlled studies. In general,
304 the sample size was small, with 62% of the studies reporting 100 or fewer subjects.

305 Over half of the included publications were simply technical descriptions of a product.
306 Though most reported studies are of relatively affordable innovations (most under 20
307 USD), two thirds of the records did not yet specify a price point for the study technology.
308 Most importantly, all the technologies were involved in diagnosis or screening for
309 diseases—none were found to address monitoring of infections. We were, however,
310 encouraged to note that half of the identified technologies focused on LMIC priority
311 communicable diseases such as HIV, malaria and tuberculosis, although only 12%
312 addressed a neglected tropical disease.

313
314 Controlling communicable disorders requires prompt screening, diagnosis, and
315 monitoring of the infectious agent, both to treat the disease in the individual and to
316 prevent its further transmission. A plethora of diagnostic tests and procedures have
317 been available to the medical community for decades, and yet, LMICs are still burdened
318 with high levels of communicable diseases (21). This has been partly explained by poor
319 availability of timely, high-quality diagnostic testing. Diagnostic laboratories in LMICs are
320 usually poorly equipped or sparsely distributed (22), limiting their ability to provide
321 accurate and rapid information to clinicians (23). Furthermore, the costs of building and
322 maintaining laboratories tends to be prohibitive in resource-constrained settings (22),
323 and training specialized technical personnel requires further financial and logistic
324 investments that are often unavailable in these countries. Our findings seem to suggest
325 that efforts in the development of mobile technologies have also identified laboratory-
326 and imaging-based testing as key obstacles, with approximately four out of five of our
327 included studies focusing on diagnosis rather than screening or monitoring.

328

329 Furthermore, many of the diagnostic technologies we identified require the use of
330 structural appendices, optical components, or specialized laboratory equipment that
331 connect to the smartphone/tablet and its inherent software and hardware specifications.
332 Therefore, these devices are not intended to completely replace standard
333 diagnostic/screening tests and procedures, but rather to make them more accessible to
334 professionals in resource-constrained settings. That said, these innovations are also
335 limited by their disproportionate reliance on Apple iOS operating systems (as LMIC
336 mobile devices tend to run on Google Android operating systems (24,25)) and frequent
337 lack of large-scale rigorous evaluation in LMIC settings (24).

338

339 The rather small number of innovations in this sphere reflects the likely limited public
340 health impact of the presently available device marketplace. Nevertheless, testing of
341 these technologies in LMICs, the wide range of diagnostic methods employed, and the
342 approach to a variety of emerging infectious pathogens that are being diagnosed using
343 these devices are encouraging findings. These would seem to indicate that not only are
344 these technologies being developed, but some are also entering a diversification phase,
345 which may hold promise for the field (26). Future work by mHealth researchers could
346 focus on technologies that can be scaled in a way that allows for widespread and cost-
347 effective implementation in resource-constrained health systems, while also expanding
348 their use to screen and monitor diseases rather than solely diagnose them.

349

350 **Limitations**

351 Our present study has several limitations. Most importantly, we employed a restrictive
352 set of inclusion criteria, which excluded patient-facing devices and apps which digitized
353 communication, algorithms/guidelines, and clinical calculators. Such technologies may
354 have important impacts on health outcomes in resource-poor settings but were outside
355 the scope of our review. Thus, their contribution to the overall ecosystem of mHealth
356 interventions for communicable diseases in LMICs is not available here for context.
357 Next, the heterogeneity of the included studies regarding their results and
358 methodological approaches precluded us from performing a meta-analysis and
359 systematic assessment of study quality, necessitating a qualitative grading system
360 instead. Lastly, given the timeline of the search and the rapidly changing nature of the
361 field (and the infectious agent itself), studies on COVID-19 were not included.

362

363 **Conclusions**

364 This systematic review found that there are only a small number of mHealth
365 technologies that constitute novel methods of screening, diagnosing, or monitoring
366 communicable diseases of public health importance in LMICs. Randomized trials and
367 evaluations with large sample sizes of these technologies are still lacking, as are
368 applications meant to monitor diseases. Additionally, most identified products require
369 accessories or peripheral devices, and a majority rely on operating systems not
370 common in LMICs, thus likely precluding more widespread clinical use in these settings.

371

372

373 **Acknowledgements**

374 None.

375

376 **Author Contributions**

377 Study concept and design: PG, SF, BF; acquisition of data: PG, SF, BF, ABR; analysis
378 and interpretation of data: PG, SF, BF, ABR, AYC; drafting of the manuscript: PG, SF,
379 AYC; critical revision of the manuscript: PG, SF, AYC; statistical analysis: PG, SF, AYC;
380 obtained funding: PG

381

382 **Conflicts of Interest**

383 No conflicts reported. Author PG is a Chan Zuckerberg Biohub investigator.

384

385

386

387 **References**

388 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden
389 of 369 diseases and injuries in 204 countries and territories, 1990–2019: a
390 systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020
391 Oct;396(10258):1204–22.

392 2. Roth Gregory A., Johnson Catherine, Abajobir Amanuel, Abd-Allah Foad, Abera
393 Semaw Ferede, Abyu Gebre, et al. Global, Regional, and National Burden of

- 394 Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol*. 2017 Jul
395 4;70(1):1–25.
- 396 3. Coates MM, Kintu A, Gupta N, Wroe EB, Adler AJ, Kwan GF, et al. Burden of non-
397 communicable diseases from infectious causes in 2017: a modelling study. *Lancet*
398 *Glob Health*. 2020 Dec 1;8(12):e1489–98.
- 399 4. Boutayeb A. The Burden of Communicable and Non-Communicable Diseases in
400 Developing Countries. *Handb Dis Burd Qual Life Meas*. 2010;531–46.
- 401 5. Bangert M, Molyneux DH, Lindsay SW, Fitzpatrick C, Engels D. The cross-cutting
402 contribution of the end of neglected tropical diseases to the sustainable
403 development goals. *Infect Dis Poverty*. 2017 Apr 4;6(1):73.
- 404 6. Bhutta ZA, Sommerfeld J, Lassi ZS, Salam RA, Das JK. Global burden, distribution,
405 and interventions for infectious diseases of poverty. *Infect Dis Poverty*. 2014 Jul
406 31;3:21.
- 407 7. WHO | Impacts of e-health on the outcomes of care in low- and middle-income
408 countries: where do we go from here? [Internet]. WHO. World Health Organization;
409 [cited 2021 Mar 2]. Available from: [https://www.who.int/bulletin/volumes/90/5/11-](https://www.who.int/bulletin/volumes/90/5/11-099069/en/)
410 [099069/en/](https://www.who.int/bulletin/volumes/90/5/11-099069/en/)
- 411 8. Braun R, Catalani C, Wimbush J, Israelski D. Community Health Workers and
412 Mobile Technology: A Systematic Review of the Literature. *PLOS ONE*. 2013 Jun
413 12;8(6):e65772.

- 414 9. Yager P, Domingo GJ, Gerdes J. Point-of-Care Diagnostics for Global Health. *Annu*
415 *Rev Biomed Eng.* 2008 Jul 22;10(1):107–44.
- 416 10. Peeling RW, Mabey D. Point-of-care tests for diagnosing infections in the
417 developing world. *Clin Microbiol Infect.* 2010 Aug 1;16(8):1062–9.
- 418 11. Park S, Zhang Y, Lin S, Wang TH, Yang S. Advances in Microfluidic PCR for Point-
419 of-Care Infectious Disease Diagnostics. *Biotechnol Adv.* 2011 Nov;29(6):830–9.
- 420 12. Tokel O, Yildiz UH, Inci F, Durmus NG, Ekiz OO, Turker B, et al. Portable
421 Microfluidic Integrated Plasmonic Platform for Pathogen Detection. *Sci Rep.* 2015
422 Mar 24;5(1):9152.
- 423 13. Geldsetzer P, Flores B. A systematic review of mobile applications to diagnose,
424 screen or monitor diseases of public health importance in low-resource settings.
425 [Internet]. PROSPERO 2020 CRD42020193945. [cited 2021 Jul 4]. Available from:
426 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020193945
- 427 14. About GBD [Internet]. Institute for Health Metrics and Evaluation. 2014 [cited 2021
428 Jul 4]. Available from: <http://www.healthdata.org/gbd/about>
- 429 15. Medicine - MeSH - NCBI [Internet]. [cited 2021 Jul 31]. Available from:
430 <https://www.ncbi.nlm.nih.gov/mesh/?term=medical+specialty>
- 431 16. Control of Neglected Tropical Diseases [Internet]. [cited 2022 Jun 21]. Available
432 from: <https://www.who.int/teams/control-of-neglected-tropical-diseases/overview>

- 433 17. Historical currency converter with official exchange rates from 1953 [Internet]. [cited
434 2022 Jun 11]. Available from: <https://fxtop.com/en/historical-currency-converter.php>
- 435 18. Committee on Global Health and the Future of the United States, Board on Global
436 Health, Health and Medicine Division, National Academies of Sciences,
437 Engineering, and Medicine. Global Health and the Future Role of the United States
438 [Internet]. Washington, D.C.: National Academies Press; 2017 [cited 2022 Jun 21].
439 Available from: <https://www.nap.edu/catalog/24737>
- 440 19. GBD Compare | IHME Viz Hub [Internet]. [cited 2021 May 26]. Available from:
441 <http://vizhub.healthdata.org/gbd-compare>
- 442 20. Appraise the evidence | BMJ Best Practice [Internet]. [cited 2022 Jun 21]. Available
443 from: <https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/appraise-the-evidence/>
- 444 21. Jayatilleke K. Challenges in Implementing Surveillance Tools of High-Income
445 Countries (HICs) in Low Middle Income Countries (LMICs). *Curr Treat Options Infect*
446 *Dis.* 2020;12(3):191–201.
- 447 22. Fleming KA, Horton S, Wilson ML, Atun R, DeStigter K, Flanigan J, et al. The Lancet
448 Commission on diagnostics: transforming access to diagnostics. *Lancet Lond Engl.*
449 2021;398(10315):1997–2050.
- 450 23. McNerney R. Diagnostics for Developing Countries. *Diagnostics.* 2015 May
451 19;5(2):200–9.

- 452 24. Mobile Operating System Market Share Worldwide [Internet]. StatCounter Global
453 Stats. [cited 2021 Jun 2]. Available from: [https://gs.statcounter.com/os-market-](https://gs.statcounter.com/os-market-share/mobile/worldwide)
454 [share/mobile/worldwide](https://gs.statcounter.com/os-market-share/mobile/worldwide)
- 455 25. Mobile OS market share 2019 [Internet]. Statista. [cited 2021 Mar 10]. Available
456 from: [https://www.statista.com/statistics/272698/global-market-share-held-by-](https://www.statista.com/statistics/272698/global-market-share-held-by-mobile-operating-systems-since-2009/)
457 [mobile-operating-systems-since-2009/](https://www.statista.com/statistics/272698/global-market-share-held-by-mobile-operating-systems-since-2009/)
- 458 26. Onodera R, Sengoku S. Innovation process of mHealth: An overview of FDA-
459 approved mobile medical applications. *Int J Med Inf.* 2018 Oct 1;118:65–71.
- 460